Minerva Neurosciences to Report Third Quarter 2022 Financial Results and Business Updates on November 9, 2022
Minerva Neurosciences (Nasdaq: NERV) announced it will release financial results for Q3 2022 on November 9, 2022. A webcast is scheduled for 8:30 a.m. Eastern Time to discuss these results and business updates. The archived version of the webcast will be available on the company’s website for 90 days post-event.
Minerva focuses on developing therapies for central nervous system disorders, including its lead candidate roluperidone for schizophrenia and MIN-301 for Parkinson's disease.
- Scheduled Q3 2022 financial results release on November 9, 2022.
- Focus on CNS disorders with promising pipeline: roluperidone and MIN-301.
- None.
BURLINGTON, Mass., Nov. 02, 2022 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (Nasdaq: NERV), a clinical-stage biopharmaceutical company focused on the development of therapies to treat central nervous system (CNS) disorders, today announced that it will release financial results and business updates for the third quarter of 2022 on Wednesday, November 9, 2022. The Company will host a webcast that day at 8:30 a.m. Eastern Time to discuss the results and updates.
The live conference call may be accessed here and the webcast is available on the Company’s website under Events and Presentations.
The archived webcast will be available on the Company’s website beginning approximately two hours after the event for 90 days.
About Minerva Neurosciences
Minerva Neurosciences, Inc. (Nasdaq: NERV) is a clinical-stage biopharmaceutical company focused on developing product candidates to treat central nervous system (CNS) diseases. Our goal is to transform the lives of patients with improved therapeutic options. Minerva’s portfolio of compounds includes roluperidone (MIN-101), in clinical development for negative symptoms of schizophrenia, and MIN-301, in pre-clinical development for Parkinson’s disease. For more information, please visit our website.
For more information:
Investor inquiries:
Fred Ahlholm
CFO, Minerva Neurosciences
info@minervaneurosciences.com
Media Inquiries:
Helen Shik
Principal, Shik Communications LLC
helen@shikcommunications.com
FAQ
What date will Minerva Neurosciences release its Q3 2022 financial results?
What is the purpose of the November 9, 2022 webcast by Minerva Neurosciences?
How can I access the archived webcast for Minerva Neurosciences' Q3 2022 results?
What are the main drugs in development by Minerva Neurosciences?
